Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 177

1.

Novel Approaches to Value Assessment Beyond the Cost-Effectiveness Framework.

Reed SD, Dubois RW, Johnson FR, Caro JJ, Phelps CE.

Value Health. 2019 Jun;22(6S):S18-S23. doi: 10.1016/j.jval.2019.04.1914. No abstract available.

PMID:
31200802
2.

Determining Value in Health Technology Assessment: Stay the Course or Tack Away?

Caro JJ, Brazier JE, Karnon J, Kolominsky-Rabas P, McGuire AJ, Nord E, Schlander M.

Pharmacoeconomics. 2019 Mar;37(3):293-299. doi: 10.1007/s40273-018-0742-2.

3.

Trusting the Results of Model-Based Economic Analyses: Is there a Pragmatic Validation Solution?

Ghabri S, Stevenson M, Möller J, Caro JJ.

Pharmacoeconomics. 2019 Jan;37(1):1-6. doi: 10.1007/s40273-018-0711-9.

PMID:
30187294
4.

The Use of MCDA in HTA: Great Potential, but More Effort Needed.

Marsh KD, Sculpher M, Caro JJ, Tervonen T.

Value Health. 2018 Apr;21(4):394-397. doi: 10.1016/j.jval.2017.10.001. Epub 2017 Nov 22.

5.

PATIENT-CENTERED DECISION MAKING: LESSONS FROM MULTI-CRITERIA DECISION ANALYSIS FOR QUANTIFYING PATIENT PREFERENCES.

Marsh K, Caro JJ, Zaiser E, Heywood J, Hamed A.

Int J Technol Assess Health Care. 2018 Jan;34(1):105-110. doi: 10.1017/S0266462317001118. Epub 2017 Dec 26.

PMID:
29277175
6.

Adding Events to a Markov Model Using DICE Simulation.

Caro JJ, Möller J.

Med Decis Making. 2018 Feb;38(2):235-245. doi: 10.1177/0272989X17715636. Epub 2017 Jul 5.

PMID:
28675959
7.

Validation of a DICE Simulation Against a Discrete Event Simulation Implemented Entirely in Code.

Möller J, Davis S, Stevenson M, Caro JJ.

Pharmacoeconomics. 2017 Oct;35(10):1103-1109. doi: 10.1007/s40273-017-0534-0.

8.

Comparative Effectiveness of Tacrolimus-Based Steroid Sparing versus Steroid Maintenance Regimens in Kidney Transplantation: Results from Discrete Event Simulation.

Desai VCA, Ferrand Y, Cavanaugh TM, Kelton CML, Caro JJ, Goebel J, Heaton PC.

Med Decis Making. 2017 Oct;37(7):827-843. doi: 10.1177/0272989X17700879. Epub 2017 Apr 6.

PMID:
28384413
9.

Amplifying Each Patient's Voice: A Systematic Review of Multi-criteria Decision Analyses Involving Patients.

Marsh K, Caro JJ, Hamed A, Zaiser E.

Appl Health Econ Health Policy. 2017 Apr;15(2):155-162. doi: 10.1007/s40258-016-0299-1. Review.

PMID:
27928659
10.

Model-observational bridging study on the effectiveness of ezetimibe on cardiovascular morbidity and mortality in France: A population-based study.

Ferrières J, Dallongeville J, Rossignol M, Bénichou J, Caro JJ, Getsios D, Hernandez L, Abenhaim L, Grimaldi-Bensouda L.

J Clin Lipidol. 2016 Nov - Dec;10(6):1379-1388. doi: 10.1016/j.jacl.2016.08.015. Epub 2016 Sep 7.

PMID:
27919355
11.

Reply: Letter to the Editor: About the advantages and disadvantages of discrete-event simulation for health economic analyses.

Caro JJ, Möller J.

Expert Rev Pharmacoecon Outcomes Res. 2016 Dec;16(6):653. No abstract available.

PMID:
27831819
12.

Response to Letter to the Editor Regarding Discretely Integrated Condition Event Simulation for Pharmacoeconomics.

Caro JJ.

Pharmacoeconomics. 2016 Nov;34(11):1189-1190. No abstract available.

PMID:
27619381
13.

Advantages and disadvantages of discrete-event simulation for health economic analyses.

Caro JJ, Möller J.

Expert Rev Pharmacoecon Outcomes Res. 2016 Jun;16(3):327-9. doi: 10.1586/14737167.2016.1165608. Epub 2016 Mar 25. No abstract available.

PMID:
26967022
14.

Discretely Integrated Condition Event (DICE) Simulation for Pharmacoeconomics.

Caro JJ.

Pharmacoeconomics. 2016 Jul;34(7):665-72. doi: 10.1007/s40273-016-0394-z.

PMID:
26961779
15.

Implementation of Population Dynamics In Modelling Health And Budget Impact of An Intervention for A Chronic Disease With Multiple Disease Subtypes.

Tran-Duy A, Boonen A, Caro JJ, Severens JL.

Value Health. 2015 Nov;18(7):A700. doi: 10.1016/j.jval.2015.09.2618. Epub 2015 Oct 20. No abstract available.

16.

What Is Insufficient about Validation?

Caro JJ.

Med Decis Making. 2015 Oct;35(7):817. doi: 10.1177/0272989X15598743. Epub 2015 Jul 30. No abstract available.

PMID:
26229082
17.

Psst, have I got a model for you . . .

Caro JJ.

Med Decis Making. 2015 Feb;35(2):139-41. doi: 10.1177/0272989X14559729. Epub 2014 Nov 20. No abstract available.

PMID:
25413367
18.

Decision-analytic models: current methodological challenges.

Caro JJ, Möller J.

Pharmacoeconomics. 2014 Oct;32(10):943-50. doi: 10.1007/s40273-014-0183-5.

PMID:
24986039
19.

Communicating the parameter uncertainty in the IQWiG efficiency frontier to decision-makers.

Stollenwerk B, Lhachimi SK, Briggs A, Fenwick E, Caro JJ, Siebert U, Danner M, Gerber-Grote A.

Health Econ. 2015 Apr;24(4):481-90. doi: 10.1002/hec.3041. Epub 2014 Mar 4.

20.

Use of relative effectiveness information in reimbursement and pricing decisions in Europe.

van Nooten F, Caro JJ.

J Comp Eff Res. 2013 Jan;2(1):33-44. doi: 10.2217/cer.12.71.

PMID:
24236519
21.

ISPOR-SMDM task force's recommendations for good modeling practices-reply to letter to the editor by Corro Ramos.

Caro JJ, Eddy DM, Hollingworth W, Tsevat J, McDonald KM, Wong JB, Briggs AH, Siebert U, Kuntz KM.

Value Health. 2013 Sep-Oct;16(6):1108. doi: 10.1016/j.jval.2013.06.016. No abstract available.

22.

Lopinavir/ritonavir versus darunavir plus ritonavir for HIV infection: a cost-effectiveness analysis for the United States.

Simpson KN, Pei PP, Möller J, Baran RW, Dietz B, Woodward W, Migliaccio-Walle K, Caro JJ.

Pharmacoeconomics. 2013 May;31(5):427-44. doi: 10.1007/s40273-013-0048-3.

PMID:
23620210
23.

How relevant is cost-effectiveness anyway?

Caro JJ.

Eur Heart J. 2013 Jan;34(4):245-6. No abstract available.

PMID:
23457725
24.

Medical planning and response for a nuclear detonation: a practical guide.

Coleman CN, Adams S, Adrianopoli C, Ansari A, Bader JL, Buddemeier B, Caro JJ, Casagrande R, Case C Jr, Caspary K, Chang AS, Chang HF, Chao N, Cliffer KD, Confer D, Deitchman S, Derenzo EG, Dobbs A, Dodgen D, Donnelly EH, Gorman S, Grace MB, Hatchett R, Hick JL, Hrdina C, Jones R, Kane E, Knebel A, Koerner JF, Laffan AM, Larson L, Livinski A, Mackinney J, Maidment BW, Manning R, Marinissen MJ, Martin C, Michael G, Murrain-Hill P, Nemhauser JB, Norwood AE, Nystrom S, Raheem M, Redlener I, Sheehan K, Simon SL, Taylor TP, Toner E, Wallace KS, Wieder J, Weinstock DM, Wiley AL Jr, Yeskey K, Miller CW, Whitcomb RC Jr.

Biosecur Bioterror. 2012 Dec;10(4):346-71. doi: 10.1089/bsp.2012.1025. Erratum in: Biosecur Bioterror. 2013 Mar;11(11):88. Miller, Charles W [added]; Whitcomb, Robert C Jr [added].

PMID:
23244500
25.

User-managed inventory: an approach to forward-deployment of urgently needed medical countermeasures for mass-casualty and terrorism incidents.

Coleman CN, Hrdina C, Casagrande R, Cliffer KD, Mansoura MK, Nystrom S, Hatchett R, Caro JJ, Knebel AR, Wallace KS, Adams SA.

Disaster Med Public Health Prep. 2012 Dec;6(4):408-14. doi: 10.1001/dmp.2012.46a.

PMID:
23241473
26.

How cost-effective are drugs and devices used in cardiology?

Caro JJ.

Eur Heart J. 2012 Oct;33(19):2372-3. No abstract available.

PMID:
23198294
27.

Model transparency and validation: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force--7.

Eddy DM, Hollingworth W, Caro JJ, Tsevat J, McDonald KM, Wong JB; ISPOR−SMDM Modeling Good Research Practices Task Force.

Value Health. 2012 Sep-Oct;15(6):843-50. doi: 10.1016/j.jval.2012.04.012.

28.

Modeling using discrete event simulation: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force--4.

Karnon J, Stahl J, Brennan A, Caro JJ, Mar J, Möller J; ISPOR-SMDM Modeling Good Research Practices Task Force.

Value Health. 2012 Sep-Oct;15(6):821-7. doi: 10.1016/j.jval.2012.04.013.

29.

Modeling good research practices--overview: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force--1.

Caro JJ, Briggs AH, Siebert U, Kuntz KM; ISPOR-SMDM Modeling Good Research Practices Task Force.

Value Health. 2012 Sep-Oct;15(6):796-803. doi: 10.1016/j.jval.2012.06.012.

30.

Model transparency and validation: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force-7.

Eddy DM, Hollingworth W, Caro JJ, Tsevat J, McDonald KM, Wong JB; ISPOR-SMDM Modeling Good Research Practices Task Force.

Med Decis Making. 2012 Sep-Oct;32(5):733-43.

PMID:
22990088
31.

Modeling using discrete event simulation: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force-4.

Karnon J, Stahl J, Brennan A, Caro JJ, Mar J, Möller J.

Med Decis Making. 2012 Sep-Oct;32(5):701-11.

PMID:
22990085
32.

Modeling good research practices--overview: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force-1.

Caro JJ, Briggs AH, Siebert U, Kuntz KM; ISPOR-SMDM Modeling Good Research Practices Task Force.

Med Decis Making. 2012 Sep-Oct;32(5):667-77. Review.

PMID:
22990082
33.

Optimizing the design of pragmatic trials: key issues remain.

Caro JJ, Ishak KJ.

J Comp Eff Res. 2012 Jul;1(4):319-27. doi: 10.2217/cer.12.37. Review.

PMID:
24237466
34.

Adjusting for patient crossover in clinical trials using external data: a case study of lenalidomide for advanced multiple myeloma.

Ishak KJ, Caro JJ, Drayson MT, Dimopoulos M, Weber D, Augustson B, Child JA, Knight R, Iqbal G, Dunn J, Shearer A, Morgan G.

Value Health. 2011 Jul-Aug;14(5):672-8. doi: 10.1016/j.jval.2011.02.1182.

35.
36.

Economic evaluation of clopidogrel plus aspirin for secondary prevention of cardiovascular events in Canada for patients with established cardiovascular disease: Results from the CHARISMA trial.

Chen J, Shi C, Mahoney EM, Dunn ES, Rinfret S, Caro JJ, O'Brien J, El-Hadi W, Bhatt DL, Topol EJ, Cohen DJ.

Can J Cardiol. 2011 Mar-Apr;27(2):222-31. doi: 10.1016/j.cjca.2010.12.021.

PMID:
21459271
37.

A discrete-event simulation of smoking-cessation strategies based on varenicline pivotal trial data.

Xenakis JG, Kinter ET, Ishak KJ, Ward AJ, Marton JP, Willke RJ, Davies S, Caro JJ.

Pharmacoeconomics. 2011 Jun;29(6):497-510. doi: 10.2165/11589230-000000000-00000.

PMID:
21452908
38.

Resource allocation after a nuclear detonation incident: unaltered standards of ethical decision making.

Caro JJ, DeRenzo EG, Coleman CN, Weinstock DM, Knebel AR.

Disaster Med Public Health Prep. 2011 Mar;5 Suppl 1:S46-53. doi: 10.1001/dmp.2011.14.

PMID:
21402811
39.

Scarce resources for nuclear detonation: project overview and challenges.

Coleman CN, Knebel AR, Hick JL, Weinstock DM, Casagrande R, Caro JJ, DeRenzo EG, Dodgen D, Norwood AE, Sherman SE, Cliffer KD, McNally R, Bader JL, Murrain-Hill P.

Disaster Med Public Health Prep. 2011 Mar;5 Suppl 1:S13-9. doi: 10.1001/dmp.2011.15. No abstract available.

PMID:
21402805
40.

Costs and cost-effectiveness of carotid stenting versus endarterectomy for patients at increased surgical risk: results from the SAPPHIRE trial.

Mahoney EM, Greenberg D, Lavelle TA, Natarajan A, Berezin R, Ishak KJ, Caro JJ, Yadav JS, Gray WA, Wholey MH, Cohen DJ.

Catheter Cardiovasc Interv. 2011 Mar 1;77(4):463-72. doi: 10.1002/ccd.22869.

PMID:
21351220
41.

IQWiG methods--a response to two critiques.

Caro JJ, Nord E, Siebert U, McGuire A, McGregor M, Henry D, de Pouvourville G, Atella V, Kolominsky-Rabas P.

Health Econ. 2010 Oct;19(10):1137-8. doi: 10.1002/hec.1658. No abstract available.

PMID:
20842681
42.

No head-to-head trial? simulate the missing arms.

Caro JJ, Ishak KJ.

Pharmacoeconomics. 2010;28(10):957-67. doi: 10.2165/11537420-000000000-00000.

PMID:
20831304
43.

Discrete event simulation: the preferred technique for health economic evaluations?

Caro JJ, Möller J, Getsios D.

Value Health. 2010 Dec;13(8):1056-60. doi: 10.1111/j.1524-4733.2010.00775.x. Epub 2010 Sep 3.

44.

The efficiency frontier approach to economic evaluation of health-care interventions.

Caro JJ, Nord E, Siebert U, McGuire A, McGregor M, Henry D, de Pouvourville G, Atella V, Kolominsky-Rabas P.

Health Econ. 2010 Oct;19(10):1117-27. doi: 10.1002/hec.1629.

PMID:
20575151
45.

Economic evaluation of doripenem for the treatment of nosocomial pneumonia in the US: discrete event simulation.

Kongnakorn T, Mwamburi M, Merchant S, Akhras K, Caro JJ, Nathwani D.

Curr Med Res Opin. 2010 Jan;26(1):17-24. doi: 10.1185/03007990903358980.

PMID:
19895363
46.

Case-control studies in pharmacoeconomic research: an overview.

Caro JJ, Huybrechts KF.

Pharmacoeconomics. 2009;27(8):627-34. doi: 10.2165/11314780-000000000-00000. Review.

PMID:
19712006
47.

Economic outcomes associated with microvascular complications of type 2 diabetes mellitus: results from a US claims data analysis.

Pelletier EM, Shim B, Ben-Joseph R, Caro JJ.

Pharmacoeconomics. 2009;27(6):479-90. doi: 10.2165/00019053-200927060-00004.

PMID:
19640011
48.

Adult vaccination strategies for the control of pertussis in the United States: an economic evaluation including the dynamic population effects.

Coudeville L, Van Rie A, Getsios D, Caro JJ, Crépey P, Nguyen VH.

PLoS One. 2009 Jul 16;4(7):e6284. doi: 10.1371/journal.pone.0006284.

49.

Cost-effectiveness of clopidogrel plus aspirin versus aspirin alone for secondary prevention of cardiovascular events: results from the CHARISMA trial.

Chen J, Bhatt DL, Dunn ES, Shi C, Caro JJ, Mahoney EM, Gabriel S, Jackson JD, Topol EJ, Cohen DJ.

Value Health. 2009 Sep;12(6):872-9. doi: 10.1111/j.1524-4733.2009.00529.x. Epub 2009 Mar 11.

50.

Economic evaluation of atorvastatin for prevention of recurrent stroke based on the SPARCL trial.

Kongnakorn T, Ward A, Roberts CS, O'Brien JA, Proskorovsky I, Caro JJ.

Value Health. 2009 Sep;12(6):880-7. doi: 10.1111/j.1524-4733.2009.00531.x. Epub 2009 Mar 11.

Supplemental Content

Support Center